Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

K3769

Sigma-Aldrich

KW-3902

≥98% (HPLC)

Synonym(e):

1,3-dipropyl-8-(3-noradamantyl)xanthine, 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione, MK-7418, Rolofylline

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C20H28N4O2
CAS-Nummer:
136199-02-5
Molekulargewicht:
356.46
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329817141
NACRES:
NA.77

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

solid

Löslichkeit

DMSO: 20 mg/mL
soluble

Lagertemp.

2-8°C

SMILES String

CCCN1C(=O)N(CCC)c2[nH]c(nc2C1=O)[C@]34C[C@H]5C[C@H](C[C@@H]3C5)C4

InChI

1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)/t12-,13+,14-,20-

InChIKey

PJBFVWGQFLYWCB-OYEQCZOJSA-N

Biochem./physiol. Wirkung

KW-3902 is an A1 adenosine receptor antagonist and is over 800 fold more selective for an A1 receptor versus the A2A receptor.

Leistungsmerkmale und Vorteile

This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

H-Sätze

H413

P-Sätze

P273 - P501

Gefahreneinstufungen

Aquatic Chronic 4

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Gad Cotter et al.
Journal of cardiac failure, 14(8), 631-640 (2008-10-18)
Rolofylline, an adenosine A(1) receptor antagonist, facilitates diuresis and preserves renal function in patients with acute heart failure (AHF) with renal impairment. Although not powered around any specific hypothesis, this pilot study was designed to identify an efficacious dose while
Beth Davison Weatherley et al.
Journal of cardiac failure, 16(1), 25-35 (2010-02-04)
Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and high mortality. Studies have consistently demonstrated an association between worsening renal function in
Christopher M O'Connor et al.
Circulation. Heart failure, 4(6), 724-732 (2011-09-09)
Cardiac troponin T (cTnT) elevation is common and is a predictor of outcomes in patients with acute heart failure (AHF). The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of
John R Teerlink et al.
Drug safety, 35(3), 233-244 (2012-02-22)
Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A(1)-receptor antagonist, in patients with acute heart failure.
Piotr Ponikowski et al.
European journal of heart failure, 12(11), 1238-1246 (2010-09-09)
The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown. We evaluated the haemodynamic effects of the AA(1)RA rolofylline in 59 HF patients with concomitant renal impairment (estimated creatinine
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.